What To Expect From Gilead In Q3 2025

2025-10-24 10:56:43 ET

Well, I am here again with my analysis of Gilead Sciences ( GILD ).

Since my last article, "Gilead Sciences: HIV Leadership Outshines Decline in COVID-19 Drug Sales," was published on 9/2, Gilead shares have risen 8.8%, outperforming the S&P 500 ( SPY ) [5.6% return], as well as the 'bellwether' for the biotech retail investors, the VanEck Biotech ETF ( BBH ) [6.7%]....

Read the full article on Seeking Alpha

For further details see: